Get the Stockscreener App
5.975
10.29%
-0.685
Novavax Inc stock is traded at $5.975, with a volume of 19.95M.
It is down -10.29% in the last 24 hours and down -11.48% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$6.66
Open:
$6.605
24h Volume:
19.95M
Relative Volume:
3.39
Market Cap:
$1.04B
Revenue:
$847.25M
Net Income/Loss:
$-284.86M
P/E Ratio:
-2.6092
EPS:
-2.29
Net Cash Flow:
$-112.35M
1W Performance:
-6.79%
1M Performance:
-11.48%
6M Performance:
-32.94%
1Y Performance:
+33.67%
1-Day Range:
$5.80
$6.64
1-Week Range:
$5.80
$7.50
52-Week Range:
$5.01
$23.86
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
5.975 | 1.04B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax First Quarter 2025 Earnings: Beats Expectations - Yahoo
Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets - Benzinga
JP Morgan Lowers Price Target for NVAX, Maintains Underweight Rating | NVAX Stock News - GuruFocus
Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up - Nasdaq
Analysts Just Shipped An Incredible Upgrade To Their Novavax, Inc. (NASDAQ:NVAX) Estimates - Yahoo Finance
Novavax (NVAX) Faces Price Target Cut Amid Regulatory Concerns | NVAX Stock News - GuruFocus
Novavax: Q1 Earnings Snapshot - New Haven Register
Novavax Inc (NVAX) Q1 2025 Earnings Call Highlights: Revenue Surge Amid Strategic Partnerships ... - Yahoo Finance
Novavax Inc (NVAX) Q1 2025 Earnings Call Highlights: Revenue Surge Amid Strategic Partnerships and Challenges - GuruFocus
Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus
Novavax (NVAX) Sets Sights on Profitability with Strategic Shifts - GuruFocus
Novavax (NVAX) Shares Surge After Upbeat Q1 Results and Raised R - GuruFocus
Health Care Stocks See Mixed Results In Market Movements - Finimize
Novavax projects $1.025B 2025 revenue framework with focus on partnerships - MSN
Novavax (NVAX) Eyes Resolution with FDA for Covid Vaccine Approval | NVAX Stock News - GuruFocus
Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears - Reuters
Why This Shrinking Covid-19 Vaccine Stock Jumped 30% - Barron's
COVID Vaccine Maker Novavax Stock Soars 16%Here's Why - Yahoo Finance
Novavax (NVAX) Set to Release Q1 Earnings with Strong Revenue Gr - GuruFocus
FDA advisory panel to discuss makeup of updated COVID shots - Seeking Alpha
Novavax Hauls in $666M Q1 Windfall, Boosts FY25 Outlook - Yahoo Finance
Thursday's Top 5 Trending Stocks: What's Going On With D-Wave, Novavax, Carvana? - Benzinga
Novavax Stock Rallies On Upbeat Q1 Earnings, Revised Full-Year Revenue Forecast: Retail’s Elated By Stocktwits - Investing.com India
Earnings call transcript: Novavax Q1 2025 Surpasses Expectations with Strong Revenue Growth - Investing.com
Novavax Stock Rallies On Upbeat Q1 Earnings, Revised Full-Year Revenue Forecast: Retail’s Elated - MSN
Novavax earnings beat by $3.36, revenue topped estimates - Investing.com
Novavax stock soars 20% as Q1 results crush estimates By Investing.com - Investing.com Australia
Novavax swings to profit on lower expenses related to COVID shots - WHTC
Novavax rises after massive Q1 beat, guidance raise - MSN
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
NVAX Earnings: Novavax Stock Soars 33% in Pre-Market on Explosive Q1 Profit - TipRanks
Novavax Q1 2025 slides: Revenue surges to $667M, company raises full-year guidance - Investing.com Australia
Novavax (NVAX) Reports Strong Q1 Earnings Boosted by APA Terminations - GuruFocus
Novavax (NVAX) Exceeds Q1 Expectations with Strong Earnings and Revenue - GuruFocus
Novavax (NVAX) Shares Surge After Upbeat Q1 Results and Raised Revenue Outlook - GuruFocus
Novavax Inc. Q1 2025 Earnings: EPS of $0.71, Revenue Surges to $667 Million, Exceeding Estimates - GuruFocus
Novavax jumps after vaccine maker swings to profit in first quarter - TradingView
Earnings snapshot: Novavax Q1 tops estimates; updates FY25 outlook - Seeking Alpha
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights | NVAX Stock News - GuruFocus
Novavax Swings To Profit As COVID-19 Vaccine Costs Drop - Finimize
NOVAVAX INC SEC 10-Q Report - TradingView
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights - PR Newswire
Novavax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 - Longview News-Journal
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 - marketscreener.com
Novavax (NVAX) Set to Release Q1 Earnings with Strong Revenue Growth Forecast - GuruFocus
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 | NVAX Stock News - GuruFocus
Novavax to Participate in BofA Securities 2025 Health Care Conference | NVAX Stock News - GuruFocus
Novavax to Participate in BofA Securities 2025 Health Care Conference - Longview News-Journal
How to Take Advantage of moves in (NVAX) - news.stocktradersdaily.com
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novavax Inc Stock (NVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Trizzino John | President and COO |
Mar 07 '25 |
Option Exercise |
0.00 |
28,890 |
0 |
82,015 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 07 '25 |
Option Exercise |
0.00 |
12,223 |
0 |
75,155 |
| Trizzino John | President and COO |
Mar 01 '25 |
Option Exercise |
0.00 |
48,000 |
0 |
76,310 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
4,000 |
0 |
33,187 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 01 '25 |
Option Exercise |
0.00 |
58,667 |
0 |
91,269 |
| Jacobs John C | President and CEO |
Mar 01 '25 |
Option Exercise |
0.00 |
83,334 |
0 |
175,183 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
59,600 |
0 |
73,825 |
| Jacobs John C | President and CEO |
Jan 23 '25 |
Option Exercise |
0.00 |
83,196 |
0 |
130,722 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Dec 31 '24 |
Option Exercise |
0.00 |
35,000 |
0 |
49,508 |
| Rodgers Richard J | Director |
Oct 29 '24 |
Option Exercise |
0.00 |
3,800 |
0 |
14,270 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):